SCHEMBL5652737

SCHEMBL5652737

COc1ccc(Cl)cc1N1CCN(CCCNC(=O)c2ccc(-c3nc4c[nH]cnc-4n3)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.57
SLC6A4 P31645 1/20 0.57
DRD2 P14416 11/20 0.56
DRD3 P35462 11/20 0.56
DRD4 P21917 5/20 0.55
HTR1A P08908 4/20 0.55
HTR2A P28223 3/20 0.55
HTR2C P28335 3/20 0.55
KCNH2 Q12809 1/20 0.54
ADRA2A P08913 1/20 0.53
HTR2B P41595 2/20 0.53
CYP1A2 P05177 1/20 0.53
MAPT P10636 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ADRA1D P25100 1/20 0.53
ADRA1A P35348 1/20 0.53
ADRA1B P35368 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651513 0.89 DRD2 (0.52) SLC6A2SLC6A4DRD2DRD3DRD4
SCHEMBL5650125 0.84 DRD2 (0.60) SLC6A4DRD2DRD3DRD4HTR1A
SCHEMBL5651330 0.80 DRD2 (0.55) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL14514784 0.76 DRD2 (0.62) DRD2DRD3DRD4HTR1AADRA1D
SCHEMBL5653993 0.76 DRD3 (0.55) SLC6A4DRD2DRD3DRD4KCNH2
SCHEMBL6053607 0.74 DRD2 (0.94) DRD2DRD3DRD4HTR1AKCNH2
SCHEMBL5653701 0.74 DRD3 (0.58) SLC6A4DRD2DRD3DRD4HTR2A
SCHEMBL5650284 0.73 DRD3 (0.58) SLC6A4DRD2DRD3HTR1AHTR2A
SCHEMBL5653116 0.73 DRD3 (0.58) SLC6A4DRD2DRD3HTR1AHTR2A
SCHEMBL3086024 0.71 DRD2 (1.00) SLC6A2SLC6A4DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 SLC6A2 2541/4885SLC6A4 3737/4885DRD2 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.